OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Your chemo is no good here: management of high-risk MCL	92
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	87
Mastocytosis demystified	63
Recognizing, defining, and managing CAR-T hematologic toxicities	60
Anticoagulation at the end of life: whether, when, and how to treat	50
Labor and delivery: DIC, HELLP, preeclampsia	42
Inpatient recognition and management of HLH	38
On the horizon: upcoming new agents for the management of ITP	37
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	30
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment	29
The varieties of therapeutic experience: navigating treatment options for patients with PNH	29
Challenges and opportunities in the long-term management of immune-mediated TTP	29
Neurological manifestations of MGUS	28
Bispecific antibody therapies	27
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	26
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	26
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	25
Where do immunotherapies stand in management of acute leukemia in adults?	24
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	24
New therapies in hemophilia: extend the half-life, mimic, or rebalance?	24
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	23
Has PD-1 blockade changed the standard of care for cHL?	23
Donor selection, graft engineering, and dosing oh my!	22
Selecting initial therapy in CLL	22
Divergent paths: management of early relapsed follicular lymphoma	22

New approaches to tackle cytopenic myelofibrosis	22
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T - cell persistence in ALL	22
Troubleshooting heparin resistance	21
How to assess hemostasis in patients with severe liver disease	21
Fitness and frailty in myeloma	21
Optimizing outcomes in secondary AML	21
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	20
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	20
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	19
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	19
MGCS: where do we stand today?	19
BV and beyond: how to incorporate novel agents into PTCL management	19
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	19
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	19
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	19
Hematology 2022—what is complete HLA match in 2022?	18
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	18
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?	18
Management of TKI-resistant chronic phase CML	18
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?	18
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	17
Demystifying autoimmune HIT: what it is, when to test, and how to treat	17
How to manage hemostasis in patients with liver disease during interventions	17
Consumptive coagulopathy in the ICU	17
How to diagnose and manage antiphospholipid syndrome	17
What's new in hereditary hemorrhagic telangiectasia?	17
Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 202	17
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL	16
Management of limited-stage Hodgkin lymphoma	16
Management of marginal zone lymphomas	16
Atypical CML: diagnosis and treatment	16
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	15
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma	15
Organ function indications and potential improvements following curative therapy for sickle cell disease	15
Special considerations in GI bleeding in VWD patients	15
Thrombosis questions from the inpatient wards	15
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	14
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	14
Approaches to management of HIT in complex scenarios, including cardiac surgery	14
CNS prophylaxis in aggressive B-cell lymphoma	14
Management of autoimmune hemolytic anemia	14
Pregnancy management for patients with bleeding disorders	14
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	14
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	14
Transplant in AML with measurable residual disease: proceed or defer?	14
Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing	13
Cytoreduction for ET and PV: who, what, when, and how?	13
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	13
Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes	13
Treatment of VTE in the thrombocytopenic cancer patient	13

Alloimmunization and hyperhemolysis in sickle cell disease	13
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma	13
POEMS syndrome: diagnosis, treatments, and outcomes	13
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	12
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	12
Clinical manifestations of telomere biology disorders in adults	12
Ph− ALL: immunotherapy in upfront treatment	12
Pegylated interferon: the who, why, and how	12
Thrombocytopenia in pregnancy	12
What is the ideal approach—doublet, triplet, or quadruplet(s)?	12
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	12
What makes a pediatric or young adult patient an appropriate transplant candidate?	12
Demystifying the diagnosis and management of ICUS, CHIP, and CCUS	12
Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS	11
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	11
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	11
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era	11
Monoclonal gammopathy of renal significance from a hematologic perspective	11
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	11
When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?	11
Future directions in transplantation for aplastic anemia	11
Next-generation therapy for lower-risk MDS	11
Sequencing bispecific antibodies and CAR T cells for FL	10
Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD	10
Managing patients with a history of arterial disease and new venous thromboembolism	10
Should we use bisphosphonates to treat bone complications in sickle cell disease?	10
Approach to the patient with suspected hypereosinophilic syndrome	10
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	10
Novel therapies upon failure of HMA plus venetoclax	10
Managing side effects: guidance for use of immunotherapies in multiple myeloma	10
The aging hemophilia patient	10
The role of stem cell transplant (auto and allo) in PTCL and CTCL	10
What to know about rare B-cell malignancies in 2025	10